287 related articles for article (PubMed ID: 21301797)
1. mTOR links oncogenic signaling to tumor cell metabolism.
Yecies JL; Manning BD
J Mol Med (Berl); 2011 Mar; 89(3):221-8. PubMed ID: 21301797
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional control of cellular metabolism by mTOR signaling.
Yecies JL; Manning BD
Cancer Res; 2011 Apr; 71(8):2815-20. PubMed ID: 21487041
[TBL] [Abstract][Full Text] [Related]
3. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Shaw RJ
Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
[TBL] [Abstract][Full Text] [Related]
4. A growing role for mTOR in promoting anabolic metabolism.
Howell JJ; Ricoult SJ; Ben-Sahra I; Manning BD
Biochem Soc Trans; 2013 Aug; 41(4):906-12. PubMed ID: 23863154
[TBL] [Abstract][Full Text] [Related]
5. Activation of a metabolic gene regulatory network downstream of mTOR complex 1.
Düvel K; Yecies JL; Menon S; Raman P; Lipovsky AI; Souza AL; Triantafellow E; Ma Q; Gorski R; Cleaver S; Vander Heiden MG; MacKeigan JP; Finan PM; Clish CB; Murphy LO; Manning BD
Mol Cell; 2010 Jul; 39(2):171-83. PubMed ID: 20670887
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
7. The expanding role of mTOR in cancer cell growth and proliferation.
Cargnello M; Tcherkezian J; Roux PP
Mutagenesis; 2015 Mar; 30(2):169-76. PubMed ID: 25688110
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 signaling and the metabolic control of cell growth.
Ben-Sahra I; Manning BD
Curr Opin Cell Biol; 2017 Apr; 45():72-82. PubMed ID: 28411448
[TBL] [Abstract][Full Text] [Related]
9. The anticancer effects of curcumin via targeting the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway.
Tamaddoni A; Mohammadi E; Sedaghat F; Qujeq D; As'Habi A
Pharmacol Res; 2020 Jun; 156():104798. PubMed ID: 32278045
[TBL] [Abstract][Full Text] [Related]
10. Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth.
Gibbons JJ; Abraham RT; Yu K
Semin Oncol; 2009 Dec; 36 Suppl 3():S3-S17. PubMed ID: 19963098
[TBL] [Abstract][Full Text] [Related]
11. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
12. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
13. Antagonistic control of muscle cell size by AMPK and mTORC1.
Mounier R; Lantier L; Leclerc J; Sotiropoulos A; Foretz M; Viollet B
Cell Cycle; 2011 Aug; 10(16):2640-6. PubMed ID: 21799304
[TBL] [Abstract][Full Text] [Related]
14. Regulation of mammalian target of rapamycin complex 1 (mTORC1) by hypoxia: causes and consequences.
Cam H; Houghton PJ
Target Oncol; 2011 Jun; 6(2):95-102. PubMed ID: 21499767
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP.
Ricoult SJ; Yecies JL; Ben-Sahra I; Manning BD
Oncogene; 2016 Mar; 35(10):1250-60. PubMed ID: 26028026
[TBL] [Abstract][Full Text] [Related]
16. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
17. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
18. Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival.
Ma S; Venkatesh A; Langellotto F; Le YZ; Hall MN; Rüegg MA; Punzo C
Exp Eye Res; 2015 Jun; 135():1-13. PubMed ID: 25887293
[TBL] [Abstract][Full Text] [Related]
19. Connecting mTORC1 signaling to SREBP-1 activation.
Bakan I; Laplante M
Curr Opin Lipidol; 2012 Jun; 23(3):226-234. PubMed ID: 22449814
[TBL] [Abstract][Full Text] [Related]
20. MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability.
Mancini F; Teveroni E; Di Conza G; Monteleone V; Arisi I; Pellegrino M; Buttarelli M; Pieroni L; D'Onofrio M; Urbani A; Pontecorvi A; Mazzone M; Moretti F
Mol Cancer; 2017 Mar; 16(1):55. PubMed ID: 28270148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
